Future Science Group
Browse
2020-12 Vaborem -Delafloxacin_Supl.Table2_R1.docx (27.31 kB)

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 2

Download (27.31 kB)
dataset
posted on 2023-02-01, 10:06 authored by Eric Farfour, Louise Ruffier d’Epenoux, Anaelle Muggeo, Corentine Alauzet, Lise Cremet, Sophie Moussalih, Antoine Roux, Sylvie C de Verdiere, Amelie Bosphore, Stephane Corvec, Thomas GuillardThomas Guillard, Marc Vasse

Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with gradient diffusion test of meropenem–vaborbactam, delafloxacin and comparators. Results: Meropenem–vaborbactam MIC50 were 4 μg/ml for Achr, 1 μg/ml for B. cepacia, 2 μg/ml for B. cenocepacia and B. multivorans, and 32 μg/ml for Smal. Delafloxacin MIC50 were 4 μg/ml for Achr, 0.25 μg/ml for B. cepacia and B. multivorans, 2 μg/ml for B. cenocepacia, and 0.5 μg/m for Smal. meropenem–vaborbactam MICs were fourfold lower than meropenem for 28.3% Achr, 77.2% B. cepacia, 53.8% B. cenocepacia and 77.2% B. multivorans. Conclusion: Meropenem–vaborbactam and delafloxacin are in vitro active against Bcc and Achr.

History

Usage metrics

    Future Microbiology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC